-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The BEACON CRC trial evaluated the efficacy of patients with metastatic colorectal cancer± (mCRC) with BRAF V600E mutations who had progressed through 1-2 line therapy in the 1-2 line of treatment selected by the researchers for iritic or FOLFIRI combined synthesia.
in a preliminary analysis previously reported, the encorafenib-biniteni-sytoci monoanti (ENCO/BINI/CETUX; triple) and encorafenib-sytoci monoantigen (ENCO/CETUX; double)programmes improved the total survival rate (OS) and objective response rate (ORR) of such patients compared to standard treatment.
report the latest efficacy and safety data analysis results in this article.
first review the study of the trial: 665 mCRC patients with V600E mutations were randomly divided into three groups (1:1:1) and treated in triple, secondary or controlled treatment.
end points are OS and ORR.
this updated analysis includes ORR for all random patients who were followed up for an extended period of 6 months.
total survival rate (OS) triple, second and control groups were 224, 220 and 221 patients, respectively.
the mid-OS in the tri-group was 9.3 months (95% CI, 8.2 to 10.8) and the control group was 5.9 months (95% CI, 5.1 to 7.1;
OS for the second group was 9.3 months (95% CI, 8.0 to 11.3) (HR (compared to the control group) 0.61 (95% CI, 0.48 to 0.77).
ORR in the PFS probability triple, second and control groups was 26.8% (95% CI, 21.1% to 33.1%), 19.5% (95% CI, 14.5% to 25.4%) and 1.8% (95% CI, 0.5% to 4.6%) respectively.
of adverse events were consistent with the previous preliminary analysis, the rates of ≥3 adverse events in the three groups were 65.8%, 57.4% and 64.2%, respectively.
in summary, in the BEACON CRC study, encorafenib combined with sectoxides improved OS, ORR, and non-progressive lifetimes in previously treated metastatic colorectal cancer patients compared to standard chemotherapy.
based on preliminary and recent analysis, encorafenib combined with sytocides can be used as a new standard treatment for metastatic colorectal cancer patients who have previously been treated with BRAF V600E mutations.
